investigated the prevalence of BP autoantibodies in patients with Parkinson’s disease and dementia using a BP180 NC16A ELISA and immunoblotting using the BP180 ectodomain or intracellular domain (50). This evidence concerns the gene COL17A1 and Parkinson disease.